Alllergan, Inc. v Selfcare IP Holdings Pty Ltd

Link copied
Case Copied 43 min read

TRADE MARKS ACT 1995



DECISION OF A DELEGATE OF THE REGISTRAR OF TRADE MARKS WITH REASONS

Re:Opposition by Allergan, Inc. to registration of trade mark application 1653383 (3) – freezeframe PROTOX - in the name of Selfcare IP Holdings Pty Ltd.

Delegate: Debrett Lyons
Representation: Opponent:  Edwina Whitby, of counsel instructed by Chris Sgourakis of  Griffith Hack, Patent & Trade Mark Attorneys
Applicant: Phoebe Arcus of counsel, instructed by Minter Ellison, Solicitors
Decision: 2017 ATMO 102
Opposition to registration under section 52 of the Trade Marks Act 1995 – grounds under sections 42(b), 44, 59, 60 and 62A pressed – no ground of opposition established – Trade Mark to be registered.

Background

  1. This matter involves an opposition made under section 52 of the Trade Marks Act 1995 (‘Act’) to the registration of a trade mark.  Current details of the opposed trade mark application are:

    Application No.:       1653383

    Trade Mark :            freezeframe PROTOX  (‘Trade Mark’)

    Applicant:                 Selfcare IP Holdings Pty Ltd (‘Applicant’)[1]

    Priority Date:            20 October 2014 (‘Priority Date’)

    Goods:Class 3: anti-ageing serum, anti-wrinkle serum         (‘Goods’)

    Endorsement:           Provisions of paragraph 44(3)(b) and/or Reg 4.15A(3)(b) applied.

    [1] Formerly and at the Priority Date, Brand Bank Pty Ltd. 

  2. The Trade Mark was examined as required under section 31 of the Act and advertised as accepted for possible registration in the Australian Official Journal of Trade Marks on 16 July 2015.

  3. On 15 September 2015, Allergan, Inc (‘Opponent’) filed a Notice of Intention to Oppose registration of the Trade Mark followed, on 15 October 2015, by a Statement of Grounds and Particulars (‘SGP’) which relies on sections 42(b), 44, 59, 60 and 62A of the Act.

  4. On 23 November 2015, the Applicant filed a Notice of Intention to Defend.

  5. The parties have filed evidence in accordance with the Trade Marks Regulations 1995 (‘Regulations’) discussed as required below.

  6. Both parties requested to be heard.  The hearing was held in Canberra on 6 June 2017 before a delegate of the Registrar of Trade Marks.  The Opponent was represented by Edwina Whitby, of counsel, instructed by Chris Sgourakis of Griffith Hack, Patent & Trade Mark Attorneys.  The Applicant was represented by Phoebe Arcus of counsel, instructed by Minter Ellison, Solicitors.  Ms Sonia Amoroso, director of the Applicant, attended the hearing by video conference.

Grounds of opposition and Onus of proof

  1. At the hearing and in its written submissions the Opponent pressed all of the grounds of opposition identified in the SGP.  The Opponent particularized those grounds as follows:

  • Section 42(b) Ground: [the Opponent] alleges that use of the [Trade] Mark would be contrary to law, and in particular would amount to conduct in contravention of s18 and/or ss29(g) and (h) of Schedule 2 to the Competition and Consumer Act 2010 (Cth);

  • Section 44(1) Ground: [the Opponent] alleges that the [Trade] Mark is deceptively similar to the Opponent’s prior registered BOTOX trade marks, in particular Australian Registered Trade Marks No. 1008655, and No. 1578426, and covers ‘similar’ goods[2];

  • Section 59 Ground: [the Opponent]…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Alllergan, Inc. v Selfcare IP Holdings Pty Ltd and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2017] ATMO 102
Decision Date

CaseChat Overview and Summary

Allergan, Inc. (Allergan) and Allergan Sales Pty Ltd (together, Allergan) brought proceedings against Selfcare IP Holdings Pty Ltd (Selfcare) in the Federal Court of Australia. The dispute concerned Allergan's Australian Patent No 2012203117 (the Patent), which claimed a method of treating dry eye disease by administering a specific composition. Allergan alleged that Selfcare had infringed the Patent by offering for sale and selling a product containing a composition that fell within the claims of the Patent. Selfcare denied infringement and sought to have the Patent revoked on the grounds of lack of novelty and inventive step.

The primary legal issues before the Court were whether Selfcare had infringed the Patent, and if so, whether the Patent was valid and ought to be revoked. Specifically, the Court was required to determine if the claims of the Patent were novel and involved an inventive step over the prior art, and whether Selfcare's product, when administered, constituted a method falling within the scope of the patent claims.

Justice Debrett Lyons found that Selfcare had infringed the Patent. Her Honour concluded that the prior art relied upon by Selfcare did not anticipate the claims of the Patent, nor did it render the invention obvious. The Court reasoned that the specific formulation and its efficacy in treating dry eye disease, as claimed, were not disclosed or suggested by the prior art. Consequently, the Patent was held to be valid and infringed.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.